<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Trisalicylate" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Trisalicylate</book-part-id>
      <title-group>
        <title>Trisalicylate</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>15</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Triptorelin" document-type="chapter">Triptorelin</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Troglitazone" document-type="chapter">Troglitazone</related-object>
    </book-part-meta>
    <body>
      <sec id="Trisalicylate.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Trisalicylate.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Choline magnesium trisalicylate is a nonacetylated dimer of salicylic acid that is used in the therapy of chronic arthritis and for general management of pain and fever. Trisalicylate has been linked to rare instances of acute, clinically apparent liver injury.</p>
        </sec>
        <sec id="Trisalicylate.Background">
          <title>Background</title>
          <p>Trisalicylate (trye" sa lis' i late) is a nonacetylated salicylic acid that has antiinflammatory, analgesic and antipyretic actions similar to aspirin. The antiinflammatory and analgesic effects of trisalicylate are probably mediated by its inhibition prostaglandin synthesis. Choline magnesium trisalicylate is similar in efficacy to aspirin, but is reported to have fewer side effects. Although available for several decades, it is less commonly used than typical nonsteroidal antiinflammatory agents. Trisalicylate is indicated for the treatment of chronic arthritis due to osteoarthritis or rheumatoid arthritis and for minor-to-moderate pain. Trisalicylate is available by prescription only as tablets of 500, 750 and 1000 mg in generic forms and under the brand name of Trilisate. It is also available as an oral solution. The recommended regimen is 750 to 1500 mg twice daily, based upon response and tolerance. Common side effects are intestinal upset, nausea, headache, dizziness, somnolence, tinnitus, rash and hypersensitivity reactions.</p>
        </sec>
        <sec id="Trisalicylate.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Prospective studies show that a proportion of patients taking choline magnesium trisalicylate experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation, particularly if the dose is reduced. Marked aminotransferase elevations (&#x0003e;3 fold elevated) can occur with high doses in patterns that resemble aspirin induced hepatotoxicity. At least one instance of clinically apparent liver injury with jaundice has been reported with onset within a week of starting trisalicylate and characterized by a mixed pattern of enzyme elevations and potentially severe course. Fever, rash and eosinophilia did not occur and autoantibodies were not present. Trisalicylate is probably capable of inducing Reye syndrome in a susceptible child or adolescent and, like aspirin, should be avoided in those age groups.</p>
          <p>Likelihood score: A[HD]: (well established cause of clinically apparent liver injury when given in high doses).</p>
        </sec>
        <sec id="Trisalicylate.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism of trisalicylate hepatotoxicity is likely hypersensitivity in instances of jaundice associated with standard doses. In addition, trisalicylate in high doses probably has a direct hepatotoxic effect resembling that of aspirin.</p>
        </sec>
        <sec id="Trisalicylate.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>A single case report of acute liver failure with ultimate recovery has been published. No instances of chronic liver disease or vanishing bile duct syndrome due to trisalicylate have been published. Patients with hypersensitivity to trisalicylate should probably avoid other nonacetylated salicylates.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Salicylates" document-type="chapter">Salicylates</related-object></p>
          <p>Other Drugs in the Class: <related-object link-type="booklink" source-id="livertox" document-id="Aspirin" document-type="chapter">Aspirin</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Diflunisal" document-type="chapter">Diflunisal</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Salsalate" document-type="chapter">Salsalate</related-object></p>
        </sec>
      </sec>
      <sec id="Trisalicylate.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Trisalicylate.Case_1_Serum_enzyme_elevat">
          <title>Case 1. Serum enzyme elevations during choline magnesium trisalicylate therapy.(<xref ref-type="bibr" rid="Trisalicylate.REF.1">1</xref>)</title>
          <p>A 21 year old woman had systemic lupus erythematosus, but was on no specific therapy. She developed a persistent cough that was then followed by fever, headache and fatigue. Evaluation found no specific cause and she was started on trisalicylate in a dose of 1500 mg twice daily to treat a suspected worsening of the underlying lupus erythematosus. Within four days, serum enzymes which had been mildly abnormal began to rise (Table). Trisalicylate was stopped and one day later serum ALT levels began to fall, although they were still elevated at the time of discharge and no follow up was available. Testing done on admission suggested that the fever and cough were due to cytomegalovirus infection and not to worsening of lupus erythematosus.</p>
          <sec id="Trisalicylate.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Trisalicylate.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Choline magnesium trisalicylate (3.0 g daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Mixed (R=4.5)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">1+ (enzyme elevations without jaundice)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">4 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Rapid, but not documented to be complete</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Trisalicylate.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Trisalicylate.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">None mentioned</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Trisalicylate.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Trisalicylate.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">79</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">164</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.8</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Admission for fever and headache</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">84</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">290</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">IgM anti-CMV positive</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">15</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">100</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.6</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3 hd_h_Trisalicylate.Td_1_1_1_4 hd_h_Trisalicylate.Td_1_1_1_5 hd_h_Trisalicylate.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Trisalicylate started (1.5 g twice daily)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">3 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">63</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">357</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.2</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">555</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">371</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Trisalicylate stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">7 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">1 day</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">590</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">376</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.3</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">8 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">2 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">383</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">326</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.5</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">9 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">3 days</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">190</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">275</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3 hd_h_Trisalicylate.Td_1_1_1_4 hd_h_Trisalicylate.Td_1_1_1_5 hd_h_Trisalicylate.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Patient discharged; no follow up available</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_1 hd_h_Trisalicylate.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;41</bold>
                    </td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;110</bold>
                    </td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;1.2</bold>
                    </td>
                    <td headers="hd_h_Trisalicylate.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Trisalicylate.Comment">
            <title>Comment</title>
            <p>A typical pattern of serum enzyme elevation in salicylate hepatotoxicity occurring within days of starting therapy with choline magnesium trisalicylate and improving within a few days of stopping. CMV hepatitis is also a possibility, although the timing in relationship to starting the medication favors drug induced liver injury. Salicylate hepatotoxicity is generally asymptomatic, anicteric and rapidly reversible.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Trisalicylate.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Trisalicylate &#x02013; Generic, Trilisate&#x000ae; (not available in U.S.), Generic</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Antiinflammatory Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac5d0d81-5c64-4344-850d-34946b3252b1">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Trisalicylate.CHEMICAL_FORMULA_AND_STRUC">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Trisalicylate.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Trisalicylate.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Trisalicylate.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO</th>
                <th id="hd_h_Trisalicylate.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Trisalicylate.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Trisalicylate.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Choline Magnesium Salicylate</td>
                <td headers="hd_h_Trisalicylate.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135008043">64425-90-7</ext-link>
                </td>
                <td headers="hd_h_Trisalicylate.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C7-H6-O3.C7-H5-O3.<break/> C5-H14-N-O.1/2Mg</td>
                <td headers="hd_h_Trisalicylate.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135008043" document-id-type="sid" document-type="summary" object-id="135008043" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Trisalicylate.CITED_REFERENCE">
        <title>CITED REFERENCE</title>
        <ref-list id="Trisalicylate.CITED_REFERENCE.reflist0">
          <ref id="Trisalicylate.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cersosimo</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Matthews</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity.</article-title>
              <source>Drug Intell Clin Pharm</source>
              <year>1987</year>
              <volume>21</volume>
              <fpage>621</fpage>
              <lpage>5</lpage>
              <pub-id pub-id-type="pmid">3301251</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Trisalicylate.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 15 August 2020</p>
        <ref-list id="Trisalicylate.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Trisalicylate.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Drugs used to treat rheumatic and musculospastic disease. Chapter 19: The NSAIDS. In Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams &#x00026; Williams, 1999, pp. 517-41.<annotation><p><italic toggle="yes">(Review of hepatotoxicity of salicylates published in 1999, discusses aspirin).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Trisalicylate.REF.lewis.2013">
            <mixed-citation publication-type="book">Lewis JH, Stine JG. Nonsteroidal anti-inflammatory drugs and leukotriene receptor antagonists: pathology and clinical presentation of hepatotoxicity. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd Edition. Amsterdam: Elsevier, 2013. pp. 370-402.<annotation><p><italic toggle="yes">(Expert review of liver injury caused by NSAIDs mentions that choline magnesium trisalicylate can cause hypersensitivity reactions and accompanying liver injury).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Trisalicylate.REF.burke.2006">
            <mixed-citation publication-type="book">Burke A, Smyth E, FitzGerald GA. Analgesic-antipyretic and antiinflammatory agents: pharmacotherapy of gout. Chapter 26. In, Brunton LL, Lazo JS, Parker KL, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006, pp 671-715.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Trisalicylate.REF.blechman.1979.119">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Blechman</surname>
                  <given-names>WJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lechner</surname>
                  <given-names>BL</given-names>
                </name>
              </person-group>
              <article-title>Clinical comparative evaluation of choline magnesium trisalicylate and acetylsalicylic acid in rheumatoid arthritis.</article-title>
              <source>Rheumatol Rehabil</source>
              <year>1979</year>
              <volume>18</volume>
              <fpage>119</fpage>
              <lpage>24</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Comparison of trisalicylate with aspirin in rheumatoid arthritis; trisalicylate was as effective and had fewer side effects, and no abnormal laboratory results were found on testing after 7 weeks of therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">377449</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.cersosimo.1987.621">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cersosimo</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Matthews</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity associated with choline magnesium trisalicylate: case report and review of salicylate-induced hepatotoxicity.</article-title>
              <source>Drug Intell Clin Pharm</source>
              <year>1987</year>
              <volume>21</volume>
              <fpage>621</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(21 year old woman with lupus developed rising serum aminotransferase levels when placed on trisalicylate, resolving with discontinuation: no jaundice: Case 1).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3301251</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.le_gallez.1990.71">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Le Gallez</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Bird</surname>
                  <given-names>HA</given-names>
                </name>
                <name name-style="western">
                  <surname>Wright</surname>
                  <given-names>V</given-names>
                </name>
              </person-group>
              <article-title>A comparison of choline magnesium trisalicylate and acetylsalicylic acid in patients with rheumatoid arthritis.</article-title>
              <source>Curr Med Res Opin</source>
              <year>1990</year>
              <volume>12</volume>
              <fpage>71</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Crossover 3 week study in 19 patients with rheumatoid arthritis with ALT monitoring, "as far as one could tell, there was no significant differences in the frequency of side-effects").</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2202551</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.nadkarni.1992.151">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nadkarni</surname>
                  <given-names>MM</given-names>
                </name>
                <name name-style="western">
                  <surname>Peller</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Retig</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Eosinophilic hepatitis after ingestion of choline magnesium trisalicylate.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1992</year>
              <volume>87</volume>
              <fpage>151</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(66 year old woman developed jaundice 3 days after stopping 3 day course of trisalicylate for osteoarthritis [bilirubin 7.0 rising to 14.3 mg/dL, ALT 774 U/L, Alk P 542 U/L], with severe course, but ultimate recovery; biopsy showed hepatitis with eosinophils; no rash or fever, ANA negative).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">1728115</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, NSAIDs were implicated as a sole agent in 8 cases [4 diclofenac, 2 celecoxib, 1 meloxicam and 1 oxaprozin] and as one of several agents in 3 cases [1 diclofenac, 1 celecoxib, 1 ibuprofen]; trisalicylate not mentioned).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were due to choline magnesium trisalicylate or other salicylates).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were due to choline magnesium trisalicylate or other salicylates).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Trisalicylate.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 28 were due to nonsteroid antiinflammatory agents, one to salsalate but none to choline magnesium trisalicylate).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Trisalicylate.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=trisalicylate+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Trisalicylate: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=trisalicylate">Trials on Trisalicylate: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
